Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids - PubMed (original) (raw)
. 2001 May 11;276(19):15983-9.
doi: 10.1074/jbc.M100439200. Epub 2001 Feb 22.
Affiliations
- PMID: 11279071
- DOI: 10.1074/jbc.M100439200
Free article
Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids
K Node et al. J Biol Chem. 2001.
Free article
Abstract
The epoxyeicosatrienoic acids (EETs) are products of cytochrome P450 (CYP) epoxygenases that have vasodilatory and anti-inflammatory properties. Here we report that EETs have additional fibrinolytic properties. In vascular endothelial cells, physiological concentrations of EETs, particularly 11,12-EET, or overexpression of the endothelial epoxygenase, CYP2J2, increased tissue plasminogen activator (t-PA) expression by 2.5-fold without affecting plasminogen activator inhibitor-1 expression. This increase in t-PA expression correlated with a 4-fold induction in t-PA gene transcription and a 3-fold increase in t-PA fibrinolytic activity and was blocked by the CYP inhibitor, SKF525A, but not by the calcium-activated potassium channel blocker, charybdotoxin, indicating a mechanism that does not involve endothelial cell hyperpolarization. The t-PA promoter is cAMP-responsive, and induction of t-PA gene transcription by EETs correlated with increases in intracellular cAMP levels and, functionally, with cAMP-driven promoter activity. To determine whether increases in intracellular cAMP levels were due to modulation of guanine nucleotide-binding proteins, we assessed the effects of EETs on Galpha(s) and Galpha(i2). Treatment with EETs increased Galpha(s), but not Galpha(i2), GTP-binding activity by 3.5-fold. These findings indicate that EETs possess fibrinolytic properties through the induction of t-PA and suggest that endothelial CYP2J2 may play an important role in regulating vascular hemostasis.
Similar articles
- Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids.
Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK. Sun J, et al. Circ Res. 2002 May 17;90(9):1020-7. doi: 10.1161/01.res.0000017727.35930.33. Circ Res. 2002. PMID: 12016269 - Activation of guanine nucleotide-binding proteins and induction of endothelial tissue-type plasminogen activator gene transcription by alcohol.
Miyamoto A, Yang SX, Laufs U, Ruan XL, Liao JK. Miyamoto A, et al. J Biol Chem. 1999 Apr 23;274(17):12055-60. doi: 10.1074/jbc.274.17.12055. J Biol Chem. 1999. PMID: 10207029 - Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids.
Node K, Huo Y, Ruan X, Yang B, Spiecker M, Ley K, Zeldin DC, Liao JK. Node K, et al. Science. 1999 Aug 20;285(5431):1276-9. doi: 10.1126/science.285.5431.1276. Science. 1999. PMID: 10455056 Free PMC article. - Epoxyeicosatrienoic acids and endothelium-dependent responses.
Campbell WB, Fleming I. Campbell WB, et al. Pflugers Arch. 2010 May;459(6):881-95. doi: 10.1007/s00424-010-0804-6. Epub 2010 Mar 12. Pflugers Arch. 2010. PMID: 20224870 Free PMC article. Review. - From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling.
Michaelis UR, Fleming I. Michaelis UR, et al. Pharmacol Ther. 2006 Sep;111(3):584-95. doi: 10.1016/j.pharmthera.2005.11.003. Epub 2005 Dec 27. Pharmacol Ther. 2006. PMID: 16380164 Review.
Cited by
- Rationally designed multitarget agents against inflammation and pain.
Hwang SH, Wecksler AT, Wagner K, Hammock BD. Hwang SH, et al. Curr Med Chem. 2013;20(13):1783-99. doi: 10.2174/0929867311320130013. Curr Med Chem. 2013. PMID: 23410172 Free PMC article. Review. - 8,9-Epoxyeicosatrienoic acid inhibits antibody production of B lymphocytes in mice.
Gao Y, Feng J, Ma K, Zhou Z, Zhu Y, Xu Q, Wang X. Gao Y, et al. PLoS One. 2012;7(7):e40258. doi: 10.1371/journal.pone.0040258. Epub 2012 Jul 3. PLoS One. 2012. PMID: 22802958 Free PMC article. - Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility.
Kim IH, Heirtzler FR, Morisseau C, Nishi K, Tsai HJ, Hammock BD. Kim IH, et al. J Med Chem. 2005 May 19;48(10):3621-9. doi: 10.1021/jm0500929. J Med Chem. 2005. PMID: 15887969 Free PMC article. - Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study.
Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC. Lee CR, et al. Hum Mol Genet. 2006 May 15;15(10):1640-9. doi: 10.1093/hmg/ddl085. Epub 2006 Apr 4. Hum Mol Genet. 2006. PMID: 16595607 Free PMC article. - Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.
Seubert JM, Zeldin DC, Nithipatikom K, Gross GJ. Seubert JM, et al. Prostaglandins Other Lipid Mediat. 2007 Jan;82(1-4):50-9. doi: 10.1016/j.prostaglandins.2006.05.017. Epub 2006 Jul 10. Prostaglandins Other Lipid Mediat. 2007. PMID: 17164132 Free PMC article. Review.